Table 2 Multivariate analysis of clinical factors and SE-derived signatures for overall survival and lung metastasis-free survival
| Â | Overall survival | Lung metastasis-free survival | |||||
|---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI of ratio | p-value | Â | Hazard Ratio | 95% CI of ratio | p-value | |
Primary site (extremities vs non-extremities) | 2.77 | 1.29 to 5.96 | 0.009 | Tumor Size (≤ 8 cm vs > 8 cm) | 2.70 | 1.49 to 4.91 | 0.001 |
Enneking Stage (I/II vs III) | 4.44 | 2.43 to 8.15 |  < 0.001 | ALP (< 110/150 vs ≥ 110/150) | 2.19 | 1.16 to 4.12 | 0.015 |
Tumor Size (≤ 8 cm vs > 8 cm) | 1.64 | 1.02 to 2.63 | 0.042 | SE-derived LMFS-signature (low vs high expression) | 4.85 | 1.61 to 14.61 | 0.005 |
ALP (< 110/150 vs ≥ 110/150) | 1.91 | 1.10 to 3.30 | 0.022 | – | – | – | – |
SE-derived OS-signature (low vs high expression) | 6.38 | 2.38 to 17.08 |  < 0.001 | – | – | – | – |